Bimagrumab vs Follistatin
How Bimagrumab and Follistatin compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
Bimagrumab and Follistatin come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
Bimagrumab vs Follistatin, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | Bimagrumab | Follistatin |
|---|---|---|
| What it is | Human IgG1 monoclonal antibody against activin receptors IIA and IIB (not a peptide) | Endogenous glycoprotein that binds and neutralizes myostatin and activin; sold online as a research peptide, and studied in humans only as gene therapy |
| Class / category | GH secretagogues | GH secretagogues |
| Evidence tier | Human RCT · Helped | Animal-only · Helped · none in humans |
| Studied / approved for | Obesity and overweight; Preservation of lean mass during incretin-assisted weight loss; Type 2 diabetes with overweight or obesity; Muscle-wasting disorders | Muscle growth / myostatin inhibition; Muscular dystrophy (gene therapy); Age-related muscle loss (sarcopenia) |
| US regulatory status (2026) | investigational (as of Jul 2026) | research use only (as of Jul 2026) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | No data | 14 |
| Banned in sport (WADA) | Yes — on the WADA prohibited list | Yes — on the WADA prohibited list |
| Key risks | Bimagrumab has been tested in randomized human trials, but it does not have the long-term safety record of an approved obesity medicine. Muscle spasms, diarrhea and acne were common bimagrumab-associated adverse events in BELIEVE. Adverse-event discontinuations were higher with bimagrumab alone than with placebo, semaglutide alone or the combinations, and longer Phase 3 safety data do not yet exist. | Human safety data for the injectable follistatin peptide are essentially absent. What little human safety information exists comes from small gene-therapy trials, where the localized approach was generally tolerated over the study window — which is not the same as establishing that an injected follistatin peptide is safe. Follistatin sits in pathways that also touch reproduction, inflammation and cell growth, so blocking them broadly is not consequence-free, and no long-term human data exist. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
If you want the option with more human evidence behind it
Leans toward Bimagrumab
Bimagrumab's evidence sits at human rct, a more human tier than Follistatin's animal-only. That reflects how the data was gathered, not a guarantee it works.
References
- 1.Heymsfield et al., 2026 — BELIEVE randomized Phase 2 trial (Nature Medicine)
- 2.BELIEVE study record — NCT05616013
- 3.Heymsfield et al., 2021 — bimagrumab in adults with type 2 diabetes and obesity
- 4.FDA Orphan Drug Designations and Approvals — bimagrumab
- 5.NCATS substance record — bimagrumab (UNII N15SW1DIV8)
- 6.ClinicalTrials.gov — active bimagrumab and tirzepatide obesity trial NCT06643728